プロリンクス、米国国立がん研究所におけるDNA損傷剤PLX038 (PEG~SN-38) とPARP阻害剤Rubraca® (ルカパリブ) 併用第IB相臨床試験を発表

NEXT STORY
The Global Nephrology Device Market is expected to grow from USD 11,952.37 Million in 2019 to USD 17,226.74 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.28%
PREV STORY
CORRECTION: VAXIL PROVIDES UPDATE ON PRECLINICAL EXPERIMENT
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

author_avatar
NASDAQ Market News

genedrive plc: Grant to develop and implement a point-of-care test in the NHS to avoid antibiotic-related hearing loss in newborn children

For release: 20 June 2018 The information contained within this announcement is deemed by ...

author_avatar
NASDAQ Market News

Kite Realty Group Trust to Report First Quarter 2020 Financial Results on May 6, 2020

author_avatar
NASDAQ Market News